About The Starting Gates Of The Ibio Vaccine Race?

 iBio, Inc. is one of the biotechnology company. The AMEX IBIO at company is focused on commercializing its technologies and product candidates. This is providing product development and manufacturing services to clients and collaborators. These technologies are including iBioLaunch technology and iBio Modulator. The Company is plant-based protein expression technologies for vaccines and therapeutic proteins. It is developing and commercializing select biopharmaceutical product candidates. The Company’s technology is covering products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant that are derived from human blood plasma.

The Starting Gates of the Vaccine Race

IBio (NYSEAMERICAN: IBIO) shares are having continued their pattern of volatility with recent news. The pandemic grinds on, and the world’s economies continue to look for positive signs. Thus, news regarding vaccine laggards are including iBio it has becomes a renewed source of investor hope. Trading spikes. Prices rise. This is great for traders. That’s where this stock has merit.  Investors are unsure of how to approach vaccine stocks to a large degree. Yet investors are also afraid to lose out on the next big thing. 

  • Investing Strategy and IBIO

Investors are better served to simply consider all of the potential candidate vaccines first. Second, they should be looking at the time required for vaccine development from a regulatory perspective. Vaccine commercialization is a drawn-out process. This remains true even though this pandemic which has seen expedited timelines for vaccines. Regardless, regulators are not going to push a vaccine from the pre-clinical phase to FDA approval overnight. The risks are simply too high. 

  • Most Recent Spike

IBio’s most recent price is coming on the heels of news that it had prioritized one of its candidate vaccines for primary development over another. The AMEX IBIO company simply found that is one of the vaccine candidates (IBIO-201) produced more beneficial effects than the other (IBIO-200). The release is very scant regarding any quantifiable data thereto. But this is still pre-clinical, animal testing. This candidate is not in clinical testing which is taking place with human subjects.

  • Kitchen Sink Approach

IBIO’s approach is multifaceted that of many vaccine candidate manufacturers. The company has therapeutics IBIO-200 and IBIO-201. But its strategy is also including manufacturing capability. The company is relying on something it calls FastPharming. It has a 130,000 square foot manufacturing facility in Texas. This is allowing the company the capacity to undertake contract manufacturing. It could be raised in a manufacturing and production capacity, rather than in a vaccine development capacity.  You can do stock trading with free NASDAQ TotalView.

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Leave a Reply

Your email address will not be published. Required fields are marked *